drugset / Trial / NCT05903833
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.
Timeline
- Start
- 2025-06-24
- Primary completion
- 2027-10-30
- Completion
- 2029-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 20 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | — |